Fundraising Fox

Nkarta, Inc.

NASDAQ: NKTX

South San Francisco, US · 4 known investors

nkartatx.com

Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.

BiotechHealthtech

Founders & leadership

PHPaul Hastings
Paul Hastingsin
PH
Paul H.in
PJ
Paul J. HastingsChief Executive Officer

Investors · 4

Competitors · 3

by search overlap

Companies competing with Nkarta, Inc. for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Nkarta, Inc. do?
Nkarta is a biotech company developing allogeneic CAR NK cell therapies for autoimmune diseases, aiming to offer safer and more accessible alternatives to autologous CAR-T treatments. Its lead program, NKX019, targets the CD19 antigen for B cell-mediated autoimmune conditions such as lupus nephritis and systemic sclerosis.
Who are Nkarta, Inc.'s investors?
Nkarta, Inc.'s investors include Samsara BioCapital, SR One Capital Management, New Enterprise Associates (NEA), Norwest Venture Partners.
Where is Nkarta, Inc. headquartered?
Nkarta, Inc. is headquartered in South San Francisco, US.